Get started

Compare · NVO vs VCRE

NVO vs VCRE

Side-by-side comparison of Novo Nordisk A/S (NVO) and Vicore Pharma Holding AB (VCRE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and VCRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $178.51B, about 61.0x VCRE ($2.93B).
  • NVO has been more active in the news (6 items in the past 4 weeks vs 2 for VCRE).
  • NVO has more recent analyst coverage (25 ratings vs 0 for VCRE).
MetricNVOVCRE
Company
Novo Nordisk A/S
Vicore Pharma Holding AB
Price
-
-
Market cap
$178.51B
$2.93B
1M return
+5.61%
-
1Y return
-12.30%
-
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
6
2
Recent ratings
25
0
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

VCRE

Vicore Pharma Holding AB

Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.

Latest NVO

Latest VCRE